- Home
- SGMT vs SOL Comparison
SGMT vs SOL Comparison
Compare SGMT & SOL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SGMT
- SOL
- Stock Information
- Founded
- SGMT 2006
- SOL 2005
- Country
- SGMT United States
- SOL United States
- Employees
- SGMT N/A
- SOL N/A
- Industry
- SGMT
- SOL Semiconductors
- Sector
- SGMT
- SOL Technology
- Exchange
- SGMT Nasdaq
- SOL Nasdaq
- Market Cap
- SGMT 71.2M
- SOL 84.6M
- IPO Year
- SGMT 2023
- SOL 2008
- Fundamental
- Price
- SGMT $3.55
- SOL $1.79
- Analyst Decision
- SGMT Strong Buy
- SOL Buy
- Analyst Count
- SGMT 6
- SOL 3
- Target Price
- SGMT $25.67
- SOL $3.50
- AVG Volume (30 Days)
- SGMT 392.3K
- SOL 148.5K
- Earning Date
- SGMT 05-08-2025
- SOL 05-14-2025
- Dividend Yield
- SGMT N/A
- SOL N/A
- EPS Growth
- SGMT N/A
- SOL N/A
- EPS
- SGMT N/A
- SOL N/A
- Revenue
- SGMT N/A
- SOL $85,621,000.00
- Revenue This Year
- SGMT N/A
- SOL N/A
- Revenue Next Year
- SGMT N/A
- SOL $45.37
- P/E Ratio
- SGMT N/A
- SOL N/A
- Revenue Growth
- SGMT N/A
- SOL N/A
- 52 Week Low
- SGMT $1.73
- SOL $1.04
- 52 Week High
- SGMT $7.38
- SOL $3.00
- Technical
- Relative Strength Index (RSI)
- SGMT 57.81
- SOL 63.51
- Support Level
- SGMT $3.18
- SOL $1.48
- Resistance Level
- SGMT $3.85
- SOL $1.87
- Average True Range (ATR)
- SGMT 0.27
- SOL 0.11
- MACD
- SGMT 0.01
- SOL 0.03
- Stochastic Oscillator
- SGMT 61.04
- SOL 79.49
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.
About SOL Emeren Group Ltd each representing 10 shares
Emeren Group Ltd is a renewable energy producer. Its portfolio consists of solar projects and Independent Power Producer (IPP) assets, and it also has global Battery Energy Storage System (BESS) capacity. The group specializes in the solar project lifecycle, development, and from construction to financing. It has three reportable segments; Solar power project development, EPC services, and Electricity generation. The company generates maximum revenue from Poland.